A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
Grand FH, Iqbal S, Zhang L, Russell NH, Chase A, Cross NC
Exp Hematol. 2007 Nov;35(11):1723-7. doi: 10.1016/j.exphem.2007.07.002. Epub 2007 Aug 30.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article